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A N U S C R I P T 4 1999; Keirstead and Blakemore, 1999) . Spontaneous remyelination has been shown to occur in MS but it is often incomplete or significantly impaired (Frohman et al., 2006; Chang et al., 2002; Raine and Wu, 1993) . A major reason for such limited capacity for remyelination in MS is thought to be the failure of OPCs to mature into remyelinating oligodendrocytes (Miron et al., 2011; Mi et al., 2009; Kuhlmann et al., 2008; Franklin and Ffrench-Constant, 2008; Mason et al., 2004; Stangel and Hartung, 2002) . Therefore, the development of therapeutic approaches aimed at the expansion and successful maturation of the OPC population and consequent remyelination is an important objective of MS research.
One such approach is the induction of remyelination using stem cells. Transplantation of neural precursor cells (NPCs) as well as cells expressing growth factors or hormones has been shown to induce the proliferation and differentiation of resident OPCs and facilitate remyelination in animal models of demyelination (Razavi et al., 2015; Calza et al., 2010; Einstein et al., 2009 ).
Embryonic stem cell-derived oligodendrocyte transplants have also been shown to remyelinate demyelinated spinal cord axons in rodents (Liu et al., 2000; Brustle et al., 1999) . Despite their therapeutic potential, cell-based therapies present a number of challenges, such as the proper integration of the exogenous cells into the host tissue without causing an aberrant immune response and, in the case of transplantation of cells expressing growth factors, pleiotropic and non-specific effects.
A N U S C R I P T 5 immune system through opsonization or antibody-dependent cell-mediated cytotoxicity. In addition to their molecular-tag function, some NOAbs can actively signal in different cell types.
One such class of NOAbs has been shown to actively stimulate oligodendrocytes and induce remyelination (Warrington and Rodriguez, 2010; Asakura and Rodriguez, 1998) .
rHIgM22 is the recombinant version of a human monoclonal IgM remyelination-promoting autoantibody that was derived from the serum of a patient with Waldenstӧm's macroglobulinemia . The original antibody, designated sHIgM22, was identified during a screening of sera from patients with benign monoclonal gammopathies in an attempt to isolate monoclonal autoantibodies with remyelination-promoting capabilities (Praet et al., 2014; Franco et al., 2008; Warrington et al., 2000) (see materials and methods for detailed description). rHIgM22 reproduces the key characteristics of sHIgM22. It binds myelin tracts and mature oligodendrocytes, induces calcium influx in astrocytes, OPCs and pre-mature OLs in culture (Watzlawik et al., 2013; Howe et al., 2004; Paz Soldan et al., 2003; Mitsunaga et al., 2002) , and promotes remyelination in the spinal cords of mice infected with Theiler's Murine Encephalomyelitis Virus (TMEV) (Warrington et al., 2007; Mitsunaga et al., 2002; Bieber et al., 2000) . Recently, the remyelination effect of rHIgM22 in the TMEV model was also found to promote axon health (Wootla et al., 2016) . In addition, studies using T2-weighted spinal cord magnetic resonance imaging (MRI) in TMEV-infected mice have shown that rHIgM22 enters the CNS, localizes in demyelinating lesions and reduces the lesion load (Pirko et al., 2004) . 
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The existing evidence strongly supports the remyelinating capabilities of rHIgM22 in the demyelinated spinal cord. Here, we examined the effects of rHIgM22 in the demyelinated brain.
To do so, we used mice exposed to cuprizone-induced demyelination. This model is well established as a tool for the study of non-immune system induced demyelination and spontaneous remyelination, and the examination of the effects of putative remyelinationpromoting therapeutics (Praet et al., 2014; Ransohoff, 2012; Merrill, 2009; Matsushima and Morell, 2001; Kondo et al., 1997) . It also allows for the examination of demyelination and remyelination in the presence of an intact blood brain barrier. The pattern of cuprizone-induced demyelination and spontaneous remyelination in the brain, especially the medial corpus callosum, is highly reproducible in most experimental rodents (Praet et al., 2014; Schmidt et al., 2013; Stangel and Hartung, 2002) .
To induce demyelination, mice are fed food containing cuprizone, a copper chelator that disrupts mitochondrial function in mature OLs, leading to their death and consequent demyelination of axons (Praet et al., 2014; Kipp et al., 2009; Matsushima and Morell, 2001) . Oligodendrocyte death in the medial corpus callosum starts within the first week of cuprizone exposure (Doan et al., 2013; Hesse et al., 2010; Mason et al., 2000) , leading to demyelination that is histologically detectable in the third week of cuprizone exposure, peaking approximately one (0.3% cuprizone) or two (0.2% cuprizone) weeks later (Sachs et al., 2014; Skripuletz et al., 2011; Hesse et al., A C C E P T E D M A N U S C R I P T 7 antagonized by cuprizone, but when the cuprizone diet stops at 6 weeks remyelination progresses rapidly, resulting in the complete remyelination of the lesions (Sachs et al., 2014; Gudi et al., 2009; Matsushima and Morell, 2001) .
In this study, we assessed the remyelination-promoting capabilities of rHIgM22 by examining its effects on the myelination state of the medial corpus callosum immediately after the end of a 0.3% cuprizone-containing food diet, and 2, 4 and 8 weeks later. We found that treatment with rHIgM22 promotes the differentiation of OPCs into mature oligodendrocytes and facilitates remyelination. The remyelination-enhancing effects of rHIgM22 were observed in anatomically distinct regions of the corpus callosum and followed a spatiotemporal pattern that is similar to that of the spontaneous remyelination process.
MATERIALS AND METHODS
Animal Care
All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee at Acorda Therapeutics. The study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act, with the goal of minimizing pain and distress to the animals, as well as with the goal of reducing the number of animals required. Six-week-old C57BL/6J male mice (Jackson Laboratory, Bar Harbor, ME) were allowed to acclimate to facility conditions for six days prior to initiation of cuprizone feeding. Animals were housed and maintained in a monitored environment at 68-79°F in 30-70% humidity on a twelve-hour light/dark cycle. Food was changed twice a week, and food and water were provided ad libitum. The animals were assigned into experimental study groups according
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Cuprizone Diet
To experimentally induce demyelination, seven-week-old C57BL/6J male mice were fed cuprizone-containing chow (Teklad global 14% protein rodent maintenance diet + 3% (w/w) Catalog No. TD.150134, Envigo) for 6 weeks, at which point they were switched back to standard chow (Teklad global 14% protein rodent maintenance diet; Catalog No.T.2014.15, Envigo) and allowed to recover for up to 8 weeks following cessation of the cuprizone diet.
Cuprizone was purchased from Sigma Aldrich (Catalog. No. C9012).
Test Compounds and Dosing
Recombinant human IgM22 (recombinant human-derived IgM22 with human H and L chains and a murine J chain) was produced from the master cell bank (CMC Biologics, Bothell WA).
The cell line was originally created at the Mayo Clinic in Rochester, Minnesota as described in Mitsunaga et al., 2002 (Mitsunaga et al., 2002 . Purification, characterization, release and stability testing was performed at CMC Biologics (Bothell, WA). Final drug product was created at Ajinomoto Althea (San Diego, CA). Bioactivity potency assays were performed at Acorda Therapeutics (Ardsley, NY).
The experimental groups received intraperitoneal (i.p.) injections of rHIgM22 (10mg/kg of body weight), human IgM isotype control [10mg/kg of body weight, ChromPure Human IgM (myeloma), Catalog No. 009-000-012, LotNo.114417, Jackson ImmunoResearch Laboratories, West Grove, PA], or vehicle (rHIgM22 formulation buffer; 10ml/kg of body weight).
Preparation of Tissue
For histological analysis, animals were deeply anesthetized with intraperitoneal injection of a ketamine/xylazine mix (80 mg/kg ketamine and 8 mg/kg xylazine in a volume of 8 ml/kg) and then transcardially perfused with 50 ml of ice-cold 4% paraformaldehyde in 0.1M Na 2 HPO 4 /NaH 2 PO 4 pH 7.4 buffer. Brains were removed, post-fixed in the same fixative at 4°C overnight, incubated in 30% sucrose at 4°C for 48 hours and embedded in Tissue-Tek O.C.T.
Compound (Catalog No.4583, Sakura Finetek, Torrance, CA) . Embedded brains were frozen and stored at -80°C until sectioning. Coronal sections (30μm of thickness) were taken using a cryostat. The sections were stored in cryoprotective solution (30% glycerol and 30% ethylene glycol in 0.1M Tris-HCl pH 7.4) at -20°C until further use.
Immunohistochemistry
Immunostaining on free-floating sections was performed as previously described (Pavlopoulos et al., 2011) , with minor modifications. Briefly, the collected floating sections were washed for 30 minutes in Tris-buffered saline (TBS: 0.1M Tris-HCl pH 7.4, 0.9% NaCl) and blocked/permeabilized in blocking buffer (10% FBS, 0.2%Triton X-100, 0.9% NaCl, 0.1M TrisHCl pH 7.4,) for at least 2 hours at room temperature. The slices were incubated with the primary antibodies overnight at 4°C. The following day, sections were rinsed 4 times (30 minutes each) in ice-cold Tris-buffered saline with Triton X-100 (TBST: 0.1M Tris-HCl pH 7.4, 0.9% NaCl, 0.2% Triton X-100) and then incubated with secondary antibodies conjugated with Alexa dyes at room temperature for 1 hour. Sections were then washed three times (30 minutes each) in ice-cold TBST, followed by either DAPI counterstain (in the case of Olig2/CC1 and Olig2/PDGFRα co-immunostaining) or FluoroMyelin stain (in the case of MBP immunostaining). The stained slices were rinsed one more time in TBST for 15 minutes and then
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A C C E P T E D M A N U S C R I P T 10 mounted on slides using FluorSave mounting medium (Catalog No. 345789, EMD Millipore, Waltham, MA) . For the examination of rHIgM22 in the cuprizone model, five or six mice per treatment group and time point were examined. Seven to eight animals per group and time point were used in the studies examining the effects of rHIgM22 on the uninjured corpus callosum.
Immunostainings were performed simultaneously for all mice at each time point. Each time point was examined independently.
For MBP and FluoroMyelin staining, three coronal slices representing the body of the corpus callosum at approximate levels +0.86mm, +0.5mm and -0.10mm from bregma (Paxinos brain atlas) and 1-2 coronal slices representing the splenium (approximate level: -2.06+0.1mm from bregma) were analysed for each mouse. For Olig2, CC1 and PDGFRα detection, three slices from the callosal body and two slices from the splenium, at levels similar to those used for MBP and FluoroMyelin, were analyzed. The experimenter was blinded to all treatments groups for all experiments.
FluoroMyelin Staining
FluoroMyelin green fluorescent myelin stain was performed following the manufacturer's instructions (ThermoFisher Scientific, Catalog No. F3465) . The slices were incubated with FluoroMyelin diluted in TBS (1/600) for 15 minutes at room temperature. The stained slices were washed once in TBST for 15 minutes prior to mounting. 
Image Acquisition and Analysis
The experimenter was blinded to experimental treatment for both image acquisition and analysis for all experiments. Z-series of optical sections (optical section thickness: 1.5μm) of the midline of the corpus callosum at 40X (MBP and FluoroMyelin) or 20X (Olig2, CC1 and PDGFRα) objective power were acquired with an LSM 700 confocal microscope using the ZEN 2012
Imaging Software (black edition; Zeiss, Jena, Germany). The optical section series covered the entire Z-axis (30μm) of each brain slice that was analyzed. Laser intensity and microscope acquisition settings were the same for all brain slices and groups for each time point. Image analysis and quantification were performed on the stacks of Z-series using the ZEN 2012
Imaging Software (blue edition). The corpus callosum was outlined and the FluoroMyelin and 
ACCEPTED MANUSCRIPT
A C C E P T E D M A N U S C R I P T 13
RESULTS
The recovery of myelin basic protein in the body of the corpus callosum following cuprizone withdrawal is facilitated by rHIgM22
To investigate the effects of rHIgM22 in demyelination and remyelination, we used the cuprizone model of induced toxic and reversible demyelination. Mice were fed cuprizonecontaining food for 6 weeks, at which point they were either euthanized and their brains were harvested or switched back to regular food (standard chow) and allowed to recover for 2, 4 or 8 weeks prior to euthanasia and brain harvesting ( Figure 1 ). rHIgM22 was administered in the middle (end of third week) and immediately after the end of the cuprizone diet. Thus, the mice examined at the end of cuprizone exposure were administered one dose of rHIgM22, whereas the animals examined 2, 4 or 8 weeks post-cuprizone received two injections ( Figure 1 ). We assessed the myelination state of the corpus callosum of cuprizone-fed mice treated with rHIgM22 and compared it with that of animals that underwent a similar diet but were treated with either vehicle (cuprz+veh) or human IgM isotype control antibody (cuprz+IgM) at the same time points. Age-matched mice that were fed regular food the entire time and sacrificed at the same time points as the cuprizone-fed animals were used as normal controls.
We first analyzed the expression of myelin basic protein (MBP), a component of myelin essential for CNS myelin formation (Boggs, 2006; Popko et al., 1987; Readhead et al., 1987) , using fluorescence-based immunohistochemistry. We examined MBP in the midline (central area) of the body of the corpus callosum. At the end of the cuprizone diet, the MBP staining signal was significantly reduced in all cuprizone-fed mice compared to control animals (Oneway ANOVA: F (3, 20) =20.14, p<0.0001; post hoc comparison with control using Tukey's multiple
comparisons test: cuprz+veh and cuprz+IgM: p<0.0001, cuprz+rHIgM22: p=0.0079). However, the MBP signal in the callosal body of mice treated with rHIgM22 (cuprz+rHIgM22) was significantly higher than in those receiving vehicle or IgM (Tukey's test; p=0.0432 and p=0.0229, for cuprz+veh and cuprz+IgM, respectively) ( Suppl. Table 1 ). Two weeks after returning the cuprizone-fed animals to regular food, MBP in cuprz+veh and cuprz+IgM animals remained significantly lower compared to controls (cuprz+veh: p=0.0023 and cuprz+IgM: p=0.0048). In contrast, the MBP signal in the cuprz+rHIgM22 mice was not only greater than that observed in the two other cuprizone-fed groups, but had been restored to control levels (comparison with control: p=0.7641; comparison with cuprz+veh and cuprz+IgM: p=0.0002 and p=0.0005, respectively) ( Figure 2B & E, Suppl. Figure 1A and Suppl. Table 1 ). MBP in cuprz+veh mice became comparable to controls two weeks later (four weeks of recovery; p=0.8534), whereas it remained significantly lower in the cuprz+IgM group (comparison with controls: p=0.0461). All groups of animals exhibited similar MBP levels in the body of the corpus callosum at the end of the 8-week recovery period (oneway ANOVA: F (3, 20) =1.049, p=0.3928) ( Figure 2C -E, Suppl. Figure 1A and Suppl. Table 1 ). Figure 2F shows the temporal profile of the observed changes of MBP signal levels and the enhancing effects of rHIgM22, expressed as fold difference compared to controls for each time
point. These data demonstrate that 1) the cuprizone diet protocol leads to significant reduction of MBP in the body of the corpus callosum, 2) this effect is reversible and MBP spontaneously recovers, reaching control levels 4 weeks after cuprizone cessation, and 3) treatment with rHIgM22 accelerates this recovery.
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rHIgM22 accelerates the recovery of FluoroMyelin, a marker of mature myelin, in the body of the corpus callosum
In addition to MBP, which is a myelin component, we also examined mature myelin in the body of the corpus callosum using FluoroMyelin staining, which is thought to label compact myelin (Giera et al., 2015; Schain et al., 2014; Monsma et al., 2014; Yu and Lieberman, 2013; Dugas et al., 2010; Watkins et al., 2008) . At the end of the cuprizone diet, all cuprizone-fed mice showed significant reduction of FluoroMyelin in their callosal body compared to controls (one-way ANOVA: F (3, 20) = 28.14, p<0.0001; Tukey's test, comparison with control: p<0.0001) ( Figure   3A & E, Suppl. Figure 1B ; Suppl. Table 2 ). The animals treated with rHIgM22 showed higher
FluoroMyelin staining compared to cuprizone-fed animals treated with vehicle or IgM, but this effect was not significant (Tukey's test; p=0.2932 and p=0.2209, comparison with cuprz+veh and cuprz+IgM, respectively). Two weeks after cuprizone cessation, FluoroMyelin in cuprz+veh and cuprz+IgM mice remained substantially lower than controls (fold decrease compared to control; cuprz+veh and cuprz+IgM, respectively: 0.55 and 0.47, p<0.0001) ( Figure 3B & E, Suppl. Figure 1B ; Suppl. Table 2 ). FluoroMyelin staining in rHIgM22-treated mice at this time point, however, was significantly greater compared to cuprz+veh and cuprz+IgM mice (p=0.0205 and p=0.002, respectively), and only marginally below control levels (fold decrease compared to control: 0.82, p=0.0491). Moreover, the staining signal in cuprz+rHIgM22 animals two weeks post-cuprizone was also significantly increased compared to that in the body of the corpus callosum of the same treatment group immediately at the end of the cuprizone diet, whereas this was not the case in the other two cuprizone-fed groups (6 versus 6+2 weeks; fold difference compared to controls; paired t-test within treatment group; significant effect for cuprz+rHIgM22: t (5)= 3.761, p=0.0132; no significant effect for curpz+veh and cuprz+IgM:
t (5)= 2.232, p=0.0760 and t (5)= 1.174, p=0.2932, respectively). FluoroMyelin in cuprz+rHIgM22
animals was restored to control levels two weeks later, after a total of 4 weeks of post-cuprizone recovery (Tukey's test; control vs. cuprz+IgM22: p=0.2211) ( Figure 3C & E, Suppl. Figure 1B and Suppl. Table 2 ). This was not the case, however, for the cuprz+veh and cuprz+IgM groups (significant difference between control and cuprz+veh or cuprz+IgM; p=0.0406 and p=0.0014, respectively). All groups had comparable FluoroMyelin staining at the end of the 8-week recovery period (one-way ANOVA: F (3, 20) =1.031, p=0.4002) ( Figure 3D , Suppl. Figure 1B and Suppl. Table 2 ). A summarized temporal profile of the observed changes of FluoroMyelin and the enhancing effects of rHIgM22 is shown in figure 3F . Thus, in addition to the myelin component MBP, rHIgM22 also accelerates the recovery of compact myelin in the body of the corpus callosum of the cuprizone model.
rHIgM22 also facilitates remyelination in the splenium of the corpus callosum
In addition to the body of the corpus callosum, which constitutes a significant part of the anterior half, we also examined the splenium, which is located posteriorly. We did this in order to better characterize the remyelination-promoting capabilities of rHIgM22, as recent studies have shown that anatomically distinct regions of the corpus callosum respond differently to cuprizoneinduced demyelination. Specifically, the splenium has been found to be more demyelinated than the body after 6 weeks of cuprizone exposure, but it recovers faster after cuprizone cessation (Steelman et al., 2012; Xie et al., 2010; Stidworthy et al., 2003) .
At the end of the cuprizone diet, the MBP staining signal was significantly reduced in the splenium of all groups of cuprizone-fed mice compared to standard chow control animals (one-
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A C C E P T E D M A N U S C R I P T 17 way ANOVA; F (3, 20) =19.12, p<0.0001; Tukey's test: p<0.0001 for cuprz+veh and cuprz+IgM, p=0.0188 for cuprz+rHIgM22) ( Figure 4A and C, Suppl. Figure 2A and Suppl. Similarly to what we observed in the body of the corpus callosum, treatment with rHIgM22 significantly increased MBP and facilitated its recovery in the splenium. Although the MBP staining signal in rHIgM22 treated animals was significantly lower compared to controls at the end of the cuprizone diet (p=0.0188), it was significantly higher than the other two cuprizone-fed Figure 3A and Suppl. Table 5 compared to the other cuprizone-fed animals (fold increase compared to cuprz+veh and cuprz+IgM, respectively; body: ~1.98 and ~1.8, p=0.0008 and p=0.0023; splenium: ~1.34 and ~1.57, p=0.0131 and p=0.0004; see also supplementary Table 6 ).
The fact that rHIgM22 does not affect the total numbers of OPC/OLs, indicates that the observed effect of rHIgM22 on mature oligodendrocytes is due to enhanced differentiation and not proliferation of OPCs. To confirm this further, we examined the effects of rHIgM22 on OPC numbers using co-immunostaining of Olig2 with the OPC marker PDGFRα ( Figure 4A ; Suppl. Table 8) .
Consistent with previous studies (Sachs et al., 2014; Gudi et al., 2014) , the percentage of Olig2+ cells co-expressing PDGFRα (OPCs) was significantly higher in all cuprizone-fed mice compared to standard chow-fed animals (fold increase compared to std chow; cuprz+veh, cuprz+IgM and cuprz+rHIgM22, respectively; body: 6.3, 6.6 and 2.8; splenium: 8.3, 9.9 and 3.5; Tukey's tes: cuprz+veh and cuprz+IgM: p<0.0001 for both callosal areas, cuprz+rHIgM22:p=0.0013 and p=0.0144, body and splenium respectively) ( Figure 6A Table 9 ). However, this percentage was significantly lower in rHIgM22 treated mice compared to the other two cuprizone-fed groups (fold decrease compared to cuprz+veh and cuprz+IgM; body: ~2.2 and ~1.9, p; splenium: ~2.3 and ~2.8; p<0.0001; Suppl. Table 9 ). Taken together, our data strongly suggest a specific action of rHIgM22 in promoting OPC differentiation.
The enhancing effects of rHIgM22 were specific to cuprizone-induced demyelination, as the antibody did not affect OPCs/OLs and myelin in the unlesioned corpus callosum of healthy animals. Specifically, standard chow-fed mice were injected with rHIgM22 or vehicle at 10 weeks of age, the same age as the cuprizone-fed animals were when treated with rHIgM22 or vehicle in the middle of the cuprizone diet. OPC/OLs and myelin were observed one and three weeks post-injection. The midline of the body and splenium of the corpus callosum were examined. 
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DISCUSSION
The remyelinating capability of rHIgM22 has previously been demonstrated primarily in the spinal cords of TMEV-infected mice (Warrington et al., 2007; Mitsunaga et al., 2002; . Here, we extend this evidence to the brain and a different pathological model of demyelination by demonstrating that rHIgM22 also facilitates remyelination in the corpus callosum in the mouse model of cuprizone-induced demyelination.
The effects of rHIgM22 on the myelination state of the medial corpus callosum were examined at the end of the cuprizone diet and at 2, 4 and 8 weeks after cuprizone cessation. To monitor remyelination we examined MBP and FluoroMyelin. Newly synthesized MBP and elevation of MBP positive axons in the corpus callosum of the cuprizone model are observed earlier and recover faster than components of more differentiated myelin, such as MOG and PLP (Moharregh-Khiabani et al., 2010; Lindner et al., 2008) . FluoroMyelin, on the other hand, is a lipophilic dye that labels compact myelin, the formation of which is a later step in the myelination process than the production and accumulation of MBP. Consistently, it has been shown that FluoroMyelin recovers slower than MBP in the demyelinated corpus callosum of genetically modified mice (Dugas et al., 2010) . Thus, by using these two myelin markers, we were able to acquire a detailed pattern of the progression of remyelination in the callosal body and splenium and to follow this process up to its completion, as measured by the restoration of FluoroMyelin to control levels.
Treatment with rHIgM22 resulted in restoration of both MBP and FluoroMyelin to control levels at an earlier time point compared to their spontaneous recovery. These findings demonstrate that rHIgM22 treatment accelerates remyelination and full recovery of the demyelinated corpus
callosum. The robust remyelination-promoting capability of rHIgM22 is further supported by the fact that similar enhancing effects were observed in the body of the corpus callosum and the splenium, which was severely demyelinated by cuprizone.
Our data are consistent with the previously published spatiotemporal pattern of remyelination in the corpus callosum of the cuprizone model (Steelman et al., 2012; Xie et al., 2010; Stidworthy et al., 2003) . Specifically, FluoroMyelin in the splenium of cuprz+veh animals was significantly increased two weeks after cuprizone termination and reached control levels 4 weeks postcuprizone, whereas complete recovery of FluoroMyelin in the callosal body occurred later, after 4 and before 8 weeks post-cuprizone. The observed rHIgM22-mediated enhancements in the corpus callosum followed a spatiotemporal pattern similar to that of spontaneous remyelination.
FluoroMyelin staining in the splenium of cuprz+rHIgM22 mice reached levels comparable to controls earlier than cuprz+veh and cuprz+IgM animals (2 weeks instead of 4 weeks postcuprizone), and this recovery was faster than that observed in the callosal body (4 weeks instead of 8 weeks post-cuprizone). Similarly, treatment with rHIgM22 significantly increased FluoroMyelin in the splenium but not the callosal body at the end of cuprizone exposure.
The fact that the spatiotemporal profiles of spontaneous and rHIgM22-mediated recovery of myelin in the corpus callosum are similar, strongly suggests that rHIgM22 promotes remyelination by enhancing mechanisms naturally occurring during this process. In other words, rHIgM22 might act as a trigger for the initiation of a natural reparative process that normally occurs later. Considering that rHIgM22 was administered to cuprizone-fed mice in the middle of the diet, a time point that coincides with the presence of proliferating OPCs in their corpus callosum, and the fact that its half-life in mice is ~15 hours and is not detectable in the circulation at ~48 hours (Warrington et al., 2007) , one possible action of rHIgM22 could be the early initiation
of OPC differentiation. Consistent with this idea, we find that rHIgM22 treatment results in increased numbers of mature oligodendrocytes in the corpus callosum at the end of the cuprizone diet and that this increase is due to enhancement of OPC differentiation into mature oligodendrocytes.
A recent study suggests that the primary mediators of rHIgM22-induced remyelination are promotion of OPC proliferation and survival, but not OPC differentiation into mature OLs, which is in contrast with our data (Watzlawik et al., 2013) . This hypothesis, however, is based on evidence from experiments in mixed glial and OPC cultures. Therefore, it is possible that these discrepant results are due to the absence of additional cell types and important components of the in vivo environment, such as neurons, the vasculature and, importantly, myelin, which is a primary target of rHIgM22.
It is important to note that the experimental design of this study and the observed remyelinationpromoting capabilities of rHIgM22 are markedly different from other studies examining other putative remyelinating agents in the cuprizone model, such as the anti-Lingo1 antibody (Mi et al., 2009 ). In the anti-Lingo1 study, the antibody was stereotaxically injected in the callosal body and its effects were examined at the end of the fourth and sixth week of a 6-week cuprizone diet.
Compared to untreated cuprizone-fed animals, anti-Lingo1 treatment was found to increase the levels of MBP in the body of the corpus callosum. Here, we used FluoroMyelin in addition to MBP in order to examine whether treatment with rHIgM22 affects later stages of remyelination, which indeed we show. Furthermore, by examining multiple time points after the end of the cuprizone diet and following remyelination up to its completion, we demonstrate that rHIgM22
does not only improve the myelination state of the corpus callosum but it also accelerates its full recovery to control levels, evidenced by the rHIgM22-mediated facilitation of the full recovery
of the mature myelin marker, FluoroMyelin. In addition, and in contrast to the anti-Lingo1 study, we show that rHIgM22 enhances remyelination not only in the callosal body but also in the splenium, demonstrating a beneficial effect throughout the corpus callosum. Finally, the remyelination-enhancing effects that we observe are the result of rHIgM22 administered systemically at doses that are representative of what might be used clinically, and not local injections in the brain, which was the case for the anti-Lingo1 antibody.
Our data demonstrate that a single systemic dose of rHIgM22 in the middle of cuprizone exposure is capable of facilitating remyelination, as it significantly promotes OPC differentiation into mature OLs and improves the myelination state of the corpus callosum at the end of cuprizone. However, the rHIgM22-treated animals that were examined during the post-cuprizone recovery period were given an additional dose of the antibody, immediately after the end of
cuprizone. An important question, therefore, is whether the pattern of the accelerated postcuprizone recovery of the corpus callosum of animals treated twice with rHIgM22 is the result of the initial injection of the antibody or a cumulative effect of the two injections. It is possible that the observed enhancements are mainly, if not exclusively, due to the initial dose of rHIgM22.
Indeed, a study in TMEV-infected mice showed that the extent of remyelination in the spinal cord 5 weeks after two i.p. doses of rHIgM22, which were 5 weeks apart from each other, and were 40 times lower than the ones used in this study, was not different from the extent of remyelination measured at 5 or 10 weeks following a single injection of rHIgM22 (Warrington et al., 2007) .
Future studies, examining post-cuprizone recovery of callosal MBP and FluoroMyelin in animals that will have undergone the cuprizone diet protocol described here but will have been treated with rHIgM22 only once, in the middle of cuprizone exposure, will allow for the identification of
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A C C E P T E D M A N U S C R I P T 25 differences, if any, between single and double-dose effects of rHIgM22 on remyelination. In addition, the identification of the antigen recognized by rHIgM22 will be important for the elucidation of its mechanism of action in OPC differentiation. Examination of the remyelinationpromoting capabilities of rHIgM22 in other brain areas and the behavioral impact of such effects will also be important for a more complete understanding of its therapeutic potential in MS and other demyelinating disorders.
CONCLUSIONS
The rHIgM22 antibody provides a promising approach to CNS remyelination with the potential to address long-term neurological deficits in MS. In addition to in vitro evidence, substantial in vivo evidence in a range of animal models supports this idea. rHIgM22 has been demonstrated to promote remyelination in the spinal cord of TMEV-infected mice. Its serum-derived homolog, sHIgM22, showed a beneficial effect in lysolecithin-induced demyelination of the mouse spinal cord. It has also been shown that even a single injection of rHIgM22 is capable of promoting substantial remyelination and improving axon health in the TMEV model. Now, our study extends the evidence supporting the therapeutic potential of rHIgM22 to a third model of demyelination, the cuprizone model, and to the brain, demonstrating enhanced OPC differentiation and robust remyelination-promoting properties following systemic administration. 
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